The Slow Adoption of Neoadjuvant Treatment for Clinical T4b Colon Cancer: A National Cancer Database Analysis
Journal of Surgical Oncology · 2025-11 · 132 (6) · 1058-1070
DOI: 10.1002/jso.70093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 19.09.2025. Verfasst von Beiqun Zhao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Colon and Rectal Surgery, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Colonic Neoplasms, Adenocarcinoma, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
BACKGROUND Emerging data support the use of neoadjuvant treatment (NAT), particularly immunotherapy in microsatellite instability–high (MSI‐H) tumors. We evaluate national trends in NAT utilization for clinical T4b colon cancers and its association with overall survival, with a focus on MSI‐H tumors. METHODS We conducted a retrospective cohort study using the National Cancer Database (2010–2022) evaluating patients with non‐metastatic clinical T4b colonic adenocarcinoma who underwent colectomy. The primary outcome measures were trends in NAT utilization and overall survival. RESULTS Among 8862 patients with clinical T4b colon cancer, NAT utilization increased over time, peaking at 28% in the most recent quartile. NAT recipients were more likely younger, healthier, and to be treated at academic centers. NAT was associated with higher R0 resection rates (83% vs 77%, p < 0.001) and significantly longer mean overall survival (105 vs 80 months, p < 0.001). Among MSI‐H patients (11% of the cohort), 15% received NAT. Immunotherapy use increased steadily, surpassing chemotherapy in 2022. Patients receiving neoadjuvant immunotherapy +/− chemotherapy demonstrated superior survival to chemotherapy alone (106 vs 85 months, p < 0.001). CONCLUSIONS Neoadjuvant therapy use has increased nationally, with a notable rise in immunotherapy for MSI‐H tumors. Neoadjuvant treatment, particularly immunotherapy, is associated with significant overall survival benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Division of Colon and Rectal Surgery, University of California, San Francisco, California, USA.
- Department of Surgery, Division of Colon and Rectal Surgery, Huntington Health -An Affiliate of Cedars-Sinai, Pasadena, California, USA.
ORCID-Profile: Adam Truong
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Zhao, B., & Truong, A. (2025). The Slow Adoption of Neoadjuvant Treatment for Clinical T4b Colon Cancer: A National Cancer Database Analysis. Journal of Surgical Oncology, 132(6), 1058-1070. https://doi.org/10.1002/jso.70093
Vancouver
Zhao B, Truong A. The Slow Adoption of Neoadjuvant Treatment for Clinical T4b Colon Cancer: A National Cancer Database Analysis. Journal of Surgical Oncology. 2025;132(6):1058-1070. doi:10.1002/jso.70093
BibTeX
@article{Zhao2025,
author = {Zhao, Beiqun and Truong, Adam},
title = {The Slow Adoption of Neoadjuvant Treatment for Clinical T4b Colon Cancer: A National Cancer Database Analysis},
journal = {Journal of Surgical Oncology},
year = {2025},
volume = {132},
number = {6},
pages = {1058--1070},
doi = {10.1002/jso.70093}
}
EUVIMED